KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

Core Viewpoint - KalVista Pharmaceuticals has received approval from the European Commission and Swissmedic for EKTERLY (sebetralstat), marking it as the first and only oral on-demand treatment for hereditary angioedema (HAE) in Europe [1] Company Summary - KalVista Pharmaceuticals, Inc. is focused on developing innovative treatments for rare diseases, specifically targeting hereditary angioedema with its new product EKTERLY [1] - The approval of EKTERLY is significant as it provides a new therapeutic option for adults and adolescents aged 12 years and older suffering from acute attacks of HAE [1] Industry Summary - The approval of EKTERLY highlights advancements in the treatment of hereditary angioedema, a condition that has limited treatment options available [1] - The introduction of an oral plasma kallikrein inhibitor represents a shift in the management of HAE, potentially improving patient compliance and outcomes [1]